7.90

2.46% 0.19

After Hours: 7.90

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $7.90, with a volume of 19,604. It is up +2.46% in the last 24 hours and down -6.62% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Previous Close:

$7.71

Open:

$7.7

24h Volume:

19,604

Relative Volume:

0.51

Market Cap:

$47.26M

Revenue:

$43.77M

Net Income/Loss:

$-35.04M

P/E Ratio:

-2.4292

EPS:

-3.2521

Net Cash Flow:

$-5.51M

1W Performance:

+1.41%

1M Performance:

-6.62%

6M Performance:

-32.14%

1Y Performance:

-18.60%

1-Day Range:

$7.70

$8.05

1-Week Range:

$7.40

$8.66

52-Week Range:

$6.4652

$16.52

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	7.90	46.13M	43.77M	-35.04M	-5.51M	-3.2521
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Initiated	Leerink Partners	Outperform
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

10:26 AM

Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks

10:26 AM

Apr 30, 2026

Net current asset value per share of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView

Apr 30, 2026

Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN

Apr 27, 2026

What failed trades Xilio Therapeutics (XLO)? (Slight Gain) 2026-04-27Market Expert Watchlist - Newser

Apr 27, 2026

Apr 22, 2026

XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 21, 2026

Xilio Therapeutics | 8-K: Current report - Moomoo

Apr 21, 2026

Apr 18, 2026

Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18Sector Analysis - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm

Apr 18, 2026

XLO: Xilio Therapeutics Presents Promising Preclinical Findings for XTX601 at AACR - GuruFocus

Apr 18, 2026

Apr 17, 2026

Xilio announces new preclinical data for XTX601 at AACR - TipRanks

Apr 17, 2026

Xilio Therapeutics appoints Cheryl Blanchard to board By Investing.com - Investing.com India

Apr 17, 2026

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors - Sahm

Apr 17, 2026

Apr 16, 2026

Xilio Therapeutics (XLO) grants director 10,000 stock options at $8.40 - Stock Titan

Apr 16, 2026

Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider - Stock Titan

Apr 16, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 16, 2026

Xilio Therapeutics Announces Board Changes and Committee Leadership - TipRanks

Apr 16, 2026

Xilio Therapeutics, Inc. Files 8-K Current Report with SEC – Company and Entity Information, April 2026 - Minichart

Apr 16, 2026

Xilio Therapeutics appoints Cheryl R. Blanchard as director and committee chair - Investing.com India

Apr 16, 2026

Xilio Therapeutics appoints Blanchard to its Board of Directors - TipRanks

Apr 16, 2026

Xilio Therapeutics Appoints New Board Member - Intellectia AI

Apr 16, 2026

Xilio Therapeutics appoints Cheryl Blanchard to board - Investing.com

Apr 16, 2026

Xilio Therapeutics (NASDAQ: XLO) adds Cheryl Blanchard to board roles - Stock Titan

Apr 16, 2026

Xilio Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com

Apr 16, 2026

Apr 13, 2026

Levels Update: Is Xilio Therapeutics Inc attractive for institutional investorsRate Hike & Risk Managed Investment Signals - baoquankhu1.vn

Apr 13, 2026

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - ADVFN

Apr 13, 2026

Apr 12, 2026

Certain Series C common stock warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Certain Pre-Funded Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Certain Stock Options of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Certain Common Stock of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com

Apr 12, 2026

Apr 10, 2026